

Altamira Therapeutics Ltd (CYTO) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/ADEF4B5EC4EEN.html>

Date: November 2021

Pages: 42

Price: US\$ 125.00 (Single User License)

ID: ADEF4B5EC4EEN

Abstracts

Altamira Therapeutics Ltd (CYTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Altamira Therapeutics Ltd (Altamira Therapeutics) formerly Auris Medical Holding Ltd, is a clinical-stage biopharmaceutical company with focus on neurotology and CNS disorders. The company's pipeline product candidates are in various clinical phases intended for the treatment of acute inner ear tinnitus, post-acute inner ear tinnitus, tinnitus, Vertigo, sudden loss of hearing, antipsychotic-induced weight gain, somnolence, airborne allergens and viruses. It has research collaboration and licensing agreements with research institutions such as King's College London, Pharmaceutical and Biotechnology companies including Xigen and Inserm. Auris Medical is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd Key Recent Developments

Nov 15,2021: Altamira Therapeutics announces poster presentations at AHA Scientific Sessions 2021

Jul 06,2021: Auris Medical to develop KRAS-targeting RNA treatment for colorectal cancer as first therapeutic indication for OligoPhore technology

May 28,2021: Auris Medical Holding to Present at LD Micro Invitational XI Conference

Mar 31,2021: Auris Medical Provides Business Update and Reports Second Half and

Full Year 2020 Financial Results

Mar 24,2021: Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Altamira Therapeutics Ltd - Key Facts
Altamira Therapeutics Ltd - Key Employees
Altamira Therapeutics Ltd - Key Employee Biographies
Altamira Therapeutics Ltd - Major Products and Services
Altamira Therapeutics Ltd - History
Altamira Therapeutics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Altamira Therapeutics Ltd - Business Description
R&D Overview
Altamira Therapeutics Ltd - Corporate Strategy
Altamira Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Altamira Therapeutics Ltd - Strengths
Altamira Therapeutics Ltd - Weaknesses
Altamira Therapeutics Ltd - Opportunities
Altamira Therapeutics Ltd - Threats
Altamira Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Altamira Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD

2021

Altamira Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD

2021

Altamira Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 15, 2021: Altamira Therapeutics announces poster presentations at AHA Scientific Sessions 2021

Jul 06, 2021: Auris Medical to develop KRAS-targeting RNA treatment for colorectal cancer as first therapeutic indication for OligoPhore technology

May 28, 2021: Auris Medical Holding to Present at LD Micro Invitational XI Conference

Mar 31, 2021: Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results

Mar 24, 2021: Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, 2021

Sep 17, 2020: Auris Medical provides business update and reports first half 2020 financial results

Apr 16, 2020: Auris Medical provides business update and reports second half and full year 2019 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Altamira Therapeutics Ltd, Key Facts
Altamira Therapeutics Ltd, Key Employees
Altamira Therapeutics Ltd, Key Employee Biographies
Altamira Therapeutics Ltd, Major Products and Services
Altamira Therapeutics Ltd, History
Altamira Therapeutics Ltd, Subsidiaries
Altamira Therapeutics Ltd, Key Competitors
Altamira Therapeutics Ltd, Ratios based on current share price
Altamira Therapeutics Ltd, Annual Ratios
Altamira Therapeutics Ltd, Annual Ratios (Cont...1)
Altamira Therapeutics Ltd, Interim Ratios
Altamira Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Altamira Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Altamira Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Altamira Therapeutics Ltd, Performance Chart (2016 - 2020)

Altamira Therapeutics Ltd, Ratio Charts

Altamira Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Altamira Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Altamira Therapeutics Ltd (CYTO) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/ADEF4B5EC4EEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ADEF4B5EC4EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970